Nuventra is now Allucent
Nuventra became part of CATO-SMS, now Allucent, in May of 2021. Learn more here. CARY, N.C., May 3, 2022 – Global biopharmaceutical services leader, CATO SMS, unveiled its new name, Allucent,…
Read More
Nuventra Scientists Author Top Downloaded Journal Article in Clinical Pharmacology & Therapeutics in 2021
Nuventra is proud to announce that the article, “The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19,” was the most-downloaded article of 2021…
Read More
Nuventra Awarded FDA Grant to Develop Model Selection of PopPK Analysis for BE Studies Using Machine Learning Approaches
Nuventra is proud to announce that it was awarded a grant from the U.S. Food and Drug Administration (FDA) for the “Development of machine learning approaches to population pharmacokinetic model…
Read More
Nuventra Ranks on Inc. 5000 List for Eighth Consecutive Year
Nuventra is proud to announce that it has once again been ranked on the Inc. 5000 list for 2021. This marks the eighth year in a row that Nuventra has…
Read More
CATO SMS Acquires Nuventra to Expand Drug Development Offering Into Clinical Pharmacology
CATO SMS, a global provider of regulatory and clinical research services, announced today that it has acquired Nuventra to extend its offering into the critical area of clinical pharmacology. Headquartered…
Read More
Nuventra Announces PK/PD Innovation Fellowship with UNC Chapel Hill for the Advancement of Minorities in the Pharmaceutical Sciences
Nuventra is pleased to announce a partnership with the University of North Carolina at Chapel Hill for the joint training of clinical pharmacologists. The PK/PD Innovation Fellowship is open to…
Read More
Nuventra Client G1 Therapeutics Receives FDA Approval for COSELA™
Nuventra is pleased to congratulate its client, G1 Therapeutics, on the approval of COSELA™ (trilaciclib). The drug is the first therapy in its class to reduce the frequency of chemotherapy-induced…
Read More